<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04402489</url>
  </required_header>
  <id_info>
    <org_study_id>MT-7117-G01</org_study_id>
    <nct_id>NCT04402489</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoetic Protoporphyria or X-Linked Protoporphyria</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Development America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Development America, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the efficacy of MT-7117 on time to
      onset and severity of first prodromal symptoms (burning, tingling, or stinging) associated
      with sunlight exposure in subjects with EPP or XLP aged 12-75.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in average daily sunlight exposure time (minutes) to first prodromal symptom (burning, tingling, itching, or stinging) associated with sunlight exposure between 1 hour post sunrise and 1 hour pre-sunset at Week 26.</measure>
    <time_frame>Baseline (Week 0) and 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC).</measure>
    <time_frame>Week 26</time_frame>
    <description>PGIC: Scale from 1 to 7, where 7 is worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of sunlight-induced pain events with pain rating of 1-10 on the Likert scale during the 26-week double-blind treatment period.</measure>
    <time_frame>Baseline (Week 0) and Week 26</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline for total score in the domain of pain intensity in the PROMIS-57.</measure>
    <time_frame>Baseline (Week 0) and Week 26</time_frame>
    <description>Pain intensity: 0 to 10, where 10 is worst pain imaginable.</description>
  </other_outcome>
  <other_outcome>
    <measure>The percentage of subjects who are responders based on average daily sunlight exposure time to first prodromal symptom associated with sunlight exposure between 1 hour post sunrise and 1 hour pre-sunset defined by within-subject meaningful change.</measure>
    <time_frame>Week 26</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline for total score in the domain of physical function in the PROMIS-57.</measure>
    <time_frame>Baseline (Week 0) and Week 26</time_frame>
    <description>Physical function: 1-5, where 5 is without any difficulty.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">159</enrollment>
  <condition>EPP</condition>
  <condition>XLP</condition>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral tablet of placebo once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-7117 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet of MT-7117 Low Dose once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-7117 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet of MT-7117 High Dose once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-7117 Low Dose</intervention_name>
    <description>MT-7117 Low Dose</description>
    <arm_group_label>MT-7117 Low Dose</arm_group_label>
    <other_name>Dersimelagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-7117 High Dose</intervention_name>
    <description>MT-7117 High Dose</description>
    <arm_group_label>MT-7117 High Dose</arm_group_label>
    <other_name>Dersimelagon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Additional screening criteria check may apply for qualification.

        Inclusion Criteria:

          1. Subjects provided written informed consent to participate. For minor subjects, both
             minor assent and parental consent will be provided.

          2. Male and female subjects with a confirmed diagnosis of EPP or XLP based on medical
             history, aged 12 years to 75 years, inclusive, at Screening.

          3. Subjects have a body weight of ≥30 kg.

          4. Subjects are willing and able to travel to the study sites for all scheduled visits.

          5. In the Investigator's opinion, subject is able to understand the nature of the study
             and any risks involved in participation, and willing to cooperate and comply with the
             protocol restrictions and requirements (including travel).

          6. Female subjects who are non-lactating and have a negative urine pregnancy test at
             baseline visit prior to receiving the first dose of study drug.

          7. Female subjects of childbearing potential and male subjects with partner of
             child-bearing potential currently using/willing to use 2 effective methods of
             contraception including barrier method as described in the protocol.

        Exclusion Criteria:

          1. History or presence of photodermatoses other than EPP or XLP.

          2. Subjects who are unwilling or unable to go outside during daylight hours most days
             (e.g., between 1 hour post sunrise and 1 hour pre-sunset) during the study.

          3. Presence of clinically significant hepatobiliary disease based on LFT values at
             Screening.

          4. Subjects with AST, ALT, ALP ≥3.0 × upper limit of normal (ULN) or total bilirubin &gt;1.5
             × ULN at Screening.

          5. Subjects with or having a history (in the last 2 years) of excessive alcohol intake in
             the opinion of the Investigator.

          6. History of melanoma.

          7. Presence of melanoma and/or lesions suspicious for melanoma at Screening.

          8. History of familial melanoma (defined as having 2 or more first-degree relatives, such
             as parents, sibling and/or child).

          9. Presence of squamous cell carcinoma, basal cell carcinoma, or other malignant skin
             lesions.

             Any suspicious lesions or nevi will be evaluated. If the suspicious lesion or nevi
             cannot be resolved through biopsy or excision, the subject will be excluded from the
             study.

         10. History or presence of psychiatric disease judged to be clinically significant by the
             Investigator and which may interfere with the study evaluation and/or safety of the
             subjects.

         11. Presence of clinically significant acute or chronic renal disease based upon the
             subject's medical records including hemodialysis; and a serum creatinine level of
             greater than 1.2 mg/dL or an estimated glomerular filtration rate (eGFR) &lt;60 ml/min.

         12. Presence of any clinically significant disease or laboratory abnormality which, in the
             opinion of the Investigator, can interfere with the study objectives and/or safety of
             the subjects.

         13. Female subjects who are pregnant, lactating, or intending to become pregnant during
             the study.

         14. Treatment with phototherapy within 3 months before Randomization (Visit 2).

         15. Treatment with afamelanotide within 3 months before Randomization (Visit 2).

         16. Treatment with cimetidine within 4 weeks before Randomization (Visit 2).

         17. Treatment with antioxidant agents within 4 weeks before Randomization (Visit 2), at
             doses which, in the opinion of the Investigator, may affect study endpoints (including
             but not limited to beta-carotene, cysteine, pyridoxine).

         18. Chronic treatment with any scheduled analgesic agents including, but not limited to,
             opioids and opioid derivatives such as morphine, hydrocodone, oxycodone, fentanyl, or
             their combination with other unscheduled analgesics or non-steroidal anti-inflammatory
             drug (Percocet and Vicodin-like prescription drugs) within 4 weeks before
             Randomization (Visit 2).

             Acute use of scheduled narcotics greater than 3 months prior to randomization, OTCs,
             such as NSAIDs or aspirin for analgesia, or prior temporary use of scheduled agents
             within 3 months of screening are not excluded.

         19. Treatment with any drugs or supplements which, in the opinion of the Investigator, can
             interfere with the objectives of the study or safety of the subjects.

         20. Previous exposure to MT-7117 (this does not include placebo treated subjects).

         21. Previous treatment with any investigational agent within 12 weeks before Screening OR
             5 half-lives of the investigational product (whichever is longer).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of Medical Science</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Development America, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Information Desk, to prevent miscommunication,</last_name>
    <phone>please email:</phone>
    <email>information@mt-pharma-us.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Of Miami School Of Medicine, Center For Liver Diseases</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Newton-Brighton Dermatology Associates</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Remington-Davis Clinical Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas Medical Branch (UTMB)</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington-Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>AB T6G 2R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protoporphyria, Erythropoietic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

